Business Standard
Thursday, Feb 16, 2012
drived banner
drived banner
  Advanced Search
RSS
Content Guide
Follow us on  
||Companies & Industry||||||| 
 Section Home | News Now | Today's Paper | Q&A | People in the News | Industry News | Features | The Compass | Research & Analysis | Opinion | Corporate Results
Home > Companies & Industry Live Markets | Commodities
 

Cipla shares jump on Pfizer talk
BS Reporter / Mumbai Dec 02, 2009, 00:42 IST

Share prices of drug major Cipla surged 2.67 per cent today, following reports that the company is in talks with Pfizer, the world’s largest drug maker, and with other leading companies for major supply contracts. Its share closed at Rs 328.70 today on the Bombay Stock Exchange (BSE) today, up from Rs 320.15 at close of trading, yesterday.

Cipla confirmed the discussions, but said such negotiations are part of its ongoing business model and does not involve any stake sale or strategic collaborations.

cipla
BSE | NSE
Price  
cipla
“Cipla has always followed a model of partnership and alliances in marketing its products, particularly overseas. We are in constant dialogue with number of multinationals towards developing products, regulatory packages and ultimately supply of products from our world class facilities,” said Amar Lulla, the joint managing director.

Amar LullaPfizer is one such company with whom Cipla is in dialogue and there is nothing beyond the business discussions, he said.

Cipla, which does not market its formulations directly in major markets like the US and US, follows a business partnership model of supplying products through contracts to about 14 leading drug companies around the world. It has over 800 drug marketing registrations across the globe, including the US and Europe, said sources.

Meanwhile, analysts feel a major outsourcing deal with Pfizer could be a win-win situation for both companies. “Cipla has presence in about 180 countries and has core competence in production of anti-asthma, anti-HIV/AIDS and anti-cancer compounds. Pfizer’s two large outsourcing deals in India with both Claris Life Sciences and Aurobindo do not cover the products manufactured by Cipla,” said Ranjit Kapadia, vice-president, institutional research, with HDFC Securities.

The cost of making active pharmaceutical ingredients can be up to 50 per cent cheaper in India than the developed markets and India’s formulation development capabilities are unmatchable, said a McKinsey report on ‘India advantage’ published yesterday.

New Ipad Application :Business Standard's all new IPad App
Click here to download for free
Arrow Other Stories     
- S&P reaches 7-month high before hitting wall
- World Bank President Zoellick to step down on June 30
- Oil cos cut jet fuel prices by Rs 350/kl
- Telcos operating profit to rise 5% in 2 yrs: Crisil
- PESB recommends SS Narsing Rao for CIL's top slot
  Read Business news in 
- Now property search gets more exciting than ever before!
- High Growth Business Opportunities in Africa - Register to explore
- Save over Rs.3000 with IndianOil Citibank Card
- We live for our family. have you secured them?
- India's No. 1 Property Site. Click here to know more..
- Diseases earlier, Saving Costs, Extending Lives. Know More..
- Get 5% cashback on telephone bills with Citi
- Enjoy the journey as much as the destination. click to know more..
- Exim Bank Conclave on India - Africa Project Partnership. Know more..
- Medium-sized businesses are the engines of a smarter planet.
- Be part of it The World's Largest Aircraft.
- Creating Wealth made simple the SIP way. Know more..
- Only Developer to give a guarantee on time space & rate.
- Office 365 for professionals and small businesses.
- Buy Your Property with Our Triple Guarantee in India.
- Improve Patient Care & Experience. Click here to know more
- Win a Business Class Ticket to Europe..Know more..
-  Introduce a New Automotive Luxury Car.. know more
- Health is Wealth..... Insurance + Savings... Know More...
Sorry, comments to this story are closed
Latest Messages
SmartInvestor+ E-zine
  Pay Rs.747/- for 3 years and
  get a branded watch FREE

  Subscribe Now
Most Popular
Read
E-Mailed
Commented
   
- Kanika Datta: The importance of being SRK
- Tata Motors soars to record level as JLR propels profit
- Indicus Analytics: Distant learning
- Leela parts ways with Kempinski
- Tailor-made but not good enough
 
 More  
BUSINESS STANDARD INDIA 2012
  Now available at Special price
  Rs.395/- Only
  Buy Now
  Now available on the Kindle Store...
  BS Specials  
    Full coverage of elections in Uttar Pradesh, Punjab, Uttarakhand, Manipur and Goa
 
  Member Area Write to the Editor RSS Archives Advanced Search
  Subscribe to BS print product BS e-paper Newsletter Portfolio Tracker
  BS Products BS Hindi BS Motoring BS Books
FOR HOT PRODUCTS
BS Bazaar.com
Home | Markets & Investing | Companies & Industry | Banking & Finance | Economy & Policy | Opinion
Life & Leisure | Management & Marketing | Tech World
About Us | Partner With Us | Code of Conduct | Careers | Advertise with us| Terms & Conditions | Disclaimer | Contact Us